AN2 Therapeutics director Robin Shane Readnour disposes of 1,108 common shares worth $6,675

Reuters2026/09/11 23:46

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Director Robin Shane Readnour reported indirect sales of 1,108 AN2 Therapeutics common shares on Sep. 9, 2026.
Transactions priced at a weighted average of $6.02 per share.
Indirect beneficial ownership reported at 557,467 shares and 624,765 shares following the sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-389545), on September 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

AN2 Therapeutics director Robin Shane Readnour disposes of 1,108 common shares worth $6,675

You may also like

Crypto prices